From article: Prana Biotechnology Ltd Sponsored ADR (NASDAQ:PRAN) improves from a B to an A rating this week. Prana Biotechnology is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. The stock’s price of $4.44 is above the 50-day moving average of $2.87.
Also should note, the upgrade from B to A rating is due to "strong buying pressure" (see how Louis Navellier’s Portfolio Grader tool works), the question is from whom? I'd guess the buying at this point is a fund or funds adding. We'll see. Great stuff though.